|
Research article summary:
Knowledge-based approaches in the design and selection of compound libraries for drug discovery.
Abstract Extract:
In the past decade, the pharmaceutical industry has realized the increasing significance of impacting the early phase hit-to-lead development in the drug discovery process. In particular, knowledge-based approaches emerged and evolved to address a ... (Full abstract text below) Published 2002May
in Journal: Curr Opin Drug Discov Devel
(Language : eng)
Full Pubmed Extract
This information was retrieved, real-time, on your behalf from the public area of the Pubmed website:
1. Curr Opin Drug Discov Devel.
2002 May;5(3):400-6
Knowledge-based approaches in the design and selection of compound libraries for drug discovery.
Viswanadhan VN, Balan C, Hulme C, Cheetham JC, Sun Y
Amgen Inc, Small Molecule Drug Discovery, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA. visv@amgen.com
In the past decade, the pharmaceutical industry has realized the increasing significance of impacting the early phase hit-to-lead development in the drug discovery process. In particular, knowledge-based approaches emerged and evolved to address a multitude of issues such as absorption, distribution, metabolism and excretion (ADME), potency, toxicity and overall drugability. Each of these approaches seeks to bring together all relevant pieces of information and create a knowledge-oriented process to deploy such information in drug discovery. This review focuses on work relating to drugability, which aims at obtaining hits (or leads) that have enhanced likelihoods of leading to successful clinical candidates by medicinal chemistry efforts. The period covered in this review is from 1997 (since the publication of Lipinski's rule of 5) to March 2002.
PMID : 12058615 [PubMed - Indexed for MEDLINE]
This information is obtained from the National Library of Medicine (NLM). Abstract text and other information may be subject to copyright. Type "NLM copyright" into Google for more information.
Full Author Information
| First Name | LastName | Initials |
| Vellarkad N | Viswanadhan | VN |
| Chenera | Balan | C |
| Christopher | Hulme | C |
| Janet C | Cheetham | JC |
| Yaxiong | Sun | Y |
Affiliation: Amgen Inc, Small Molecule Drug Discovery, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA. visv@amgen.com
3rd Party provider links
Click the links below to go to related 3rd party information:
MESH categories and related page links
This article was linked to the MESH categories shown on the left below. The links on the right are related Memletics pages.
Category links from this article: | | Related Memletics topics: |
Links for this articleFor links to places where you can get the full text of this article see links. Note there may be a subscription or fee required for access to the full text. New! Using similar technology to this site, we have launched find-health-articles.com, targeting over 1 million health research article abstracts. Related ArticlesHere are some articles related to this one (by title keywords): Keywords in this article:absorption, address, adme, aims, approaches, based, bring, candidates, chemistry, clinical, covered, create, decade, deploy, development, discovery, distribution, drug, drugability, early, efforts, emerged, enhanced, evolved, excretion, focuses, hit, hits, impacting, increasing, industry, information, issues, knowledge, lead, leading, leads, likelihoods, lipinski, medicinal, metabolism, multitude, obtaining, oriented, particular, past, period, pharmaceutical, phase, pieces, potency, process, publication, realized, relating, relevant, review, rule, seeks, significance, successful, together, toxicity, work
|
